Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

December 7, 2020December 7, 2020

Takeda Partners With Universities on Research Into GI and Liver Disorders

News

Takeda Pharmaceuticals has entered a five-year research collaboration with New York University and Columbia University to discover and develop new therapies for people with gastrointestinal and liver disorders. Gut inflammation, ... Read more

August 17, 2020August 17, 2020

Budesonide Once-daily Pill Now Available in US for Crohn’s Disease

Crohn's Disease, News

Ferring Pharmaceuticals has announced the launch of Ortikos (budesonide), the first and only once-daily pill treatment for people, 8 and older, with mild to moderate Crohn’s disease, in the U.S. ... Read more

July 13, 2020July 13, 2020

Hulio, Humira Biosimilar, Gets FDA Nod for Crohn’s, UC, But Not Available Until 2023

News

The U.S. Food and Drug Administration (FDA) has approved Hulio, a biosimilar of Humira (adalimumab), for the treatment of adults with Crohn’s disease and ulcerative colitis — both forms of inflammatory bowel disease. ... Read more

March 18, 2020March 18, 2020

Data from Abivax Trial Testing ABX464 Anti-inflammatory for UC Expected by Year’s End

News

Top-line data from an international Phase 2b clinical trial evaluating ABX464, Abivax’s lead therapeutic candidate for moderate-to-severe ulcerative colitis (UC), are expected later this year, according to the company’s financial ... Read more

August 1, 2018August 1, 2018

RHB-104 Shows Promise for Crohn’s Disease Remission in Phase 3 Trial

News

RedHill Biopharma’s experimental therapy RHB-104 significantly increases the remission and response rates of patients with Crohn’s disease, according to top-line Phase 3 trial results recently announced by the company. The ... Read more

July 16, 2018July 16, 2018

Young IBD Patients at High Risk of Developing Anxiety, Depression, Researchers Say

News

Young people with inflammatory bowel disease (IBD) — especially women and those with active disease — are at greater risk of developing anxiety and depression, a Dutch study shows. These ... Read more

July 13, 2018July 13, 2018

Genetic Changes Specific to IBD-associated Colorectal Cancer May Help Identify High-risk Patients

News

Newly discovered genetic alterations that precede the development of colorectal cancer associated with inflammatory bowel disease (IBD) may help in the development of diagnostic tools to identify patients at the ... Read more

January 8, 2018January 8, 2018

Belgium Approves Extension Trial of Abivax’s Ulcerative Colitis Therapy

News

Regulators in Belgium have approved Abivax’s request for a long-term extension of the company’s ongoing Phase 2a trial of ABX464 as a treatment for ulcerative colitis. It said it expects approvals from ... Read more

January 4, 2018January 4, 2018

Protalix Therapy Eliminates Ulcerative Colitis in a Third of Patients in Phase 2 Trial

News

Protalix BioTherapeutics’ ulcerative colitis therapy OPRX-106 eradicated the disease in a third of the first 14 patients participating in a Phase 2 clinical trial. Fifty-seven percent of the patients responded to the treatment ... Read more